{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:16:01Z","timestamp":1787584561050,"version":"build-2736575974"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Although numerous drugs have been associated with cataracts, the risk for most drugs remains unclear. This study aimed to investigate the risk factors for drug-induced cataracts by analyzing large-scale data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used the reporting odds ratio (ROR) to evaluate reports of drug-induced cataracts in FAERS from the first quarter of 2004 to the third quarter of 2024. A univariate analysis, LASSO (least absolute shrinkage and selection operator) regression, and a multivariate regression analysis were performed to identify drug-related risk factors for cataracts, and Bonferroni correction was applied for multiple comparisons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Multivariate logistic regression ultimately identified 15 drugs as independent risk factors, including immunomodulators (6\/15), antineoplastic drugs (3\/15), psychotropic drugs (1\/15), respiratory drugs (1\/15), gastrointestinal drugs (1\/15), orthopedic drugs (1\/15), metabolic regulators (1\/15), and ophthalmic drugs (1\/15). The median time to onset of drug-induced cataracts was 449 days (interquartile range [IQR]: 150\u2013901 days), with approximately 75% of adverse events occurring within 747 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings may help clinicians detect drug-related cataracts at an early stage and provide valuable insights for future research on the mechanisms of drug-induced cataracts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1498191","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:11:34Z","timestamp":1745453494000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Real-world pharmacovigilance analysis of drug-related cataracts using the FDA adverse event reporting system database"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan Yang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia Feng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.sleep.2020.09.017","article-title":"The sodium in sodium oxybate: is there cause for concern?","volume":"75","author":"Avidan","year":"2020","journal-title":"Sleep. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e0166468","DOI":"10.1371\/journal.pone.0166468","article-title":"The association between systemic glucocorticoid use and the risk of cataract and glaucoma in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"11","author":"Black","year":"2016","journal-title":"PLoS One"},{"key":"B4","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s40265-019-01133-w","article-title":"Tiotropium\/olodaterol: a review in COPD","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"key":"B5","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1136\/bjo.85.5.516","article-title":"Prevention strategies for age related cataract: present limitations and future possibilities","volume":"85","author":"Congdon","year":"2001","journal-title":"Br. J. Ophthalmol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus Pomalidomide and dexamethasone versus Pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3109\/09286586.2015.1077258","article-title":"Statin use and incident cataract surgery: a case-control study","volume":"23","author":"Erie","year":"2016","journal-title":"Ophthalmic Epidemiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.schres.2019.07.049","article-title":"Associations among antipsychotics, metabolism-related diseases, and cataracts in patients with schizophrenia: a retrospective cohort study","volume":"212","author":"Fang","year":"2019","journal-title":"Schizophr. Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e002012","DOI":"10.1136\/rmdopen-2021-002012","article-title":"Long-term safety and efficacy of Upadacitinib or Adalimumab in patients with rheumatoid arthritis: results through 3 Years from the SELECT-COMPARE study","volume":"8","author":"Fleischmann","year":"2022","journal-title":"RMD Open"},{"key":"B10","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of a disproportionality analysis for DrUg safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","article-title":"Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study","volume":"9","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"B12","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of Risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/09286580902863031","article-title":"The prevalence of lens opacities in tehran: the tehran eye study","volume":"16","author":"Hashemi","year":"2009","journal-title":"Ophthalmic Epidemiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1001\/jama.295.23.2752","article-title":"Statin use and incident nuclear cataract","volume":"295","author":"Klein","year":"2006","journal-title":"JAMA"},{"key":"B15","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.diabres.2018.07.008","article-title":"Clinical usefulness of the body muscle-to-fat ratio for screening obstructive sleep apnea syndrome in patients with inadequately controlled type 2 diabetes mellitus","volume":"143","author":"Kurinami","year":"2018","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s40266-020-00745-2","article-title":"Risk of cataract surgery and age-related macular degeneration after initiation of denosumab vs zoledronic acid for osteoporosis: a multi-database cohort study","volume":"37","author":"Lee","year":"2020","journal-title":"Drugs Aging"},{"key":"B17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.bbi.2020.11.008","article-title":"Ibrutinib alleviates LPS-induced neuroinflammation and synaptic defects in a mouse model of depression","volume":"92","author":"Li","year":"2021","journal-title":"Brain Behav. Immun."},{"key":"B18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40360-025-00856-9","article-title":"Drug-related macular edema: a real-world FDA adverse event reporting system database study","volume":"26","author":"Li","year":"","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2024.2446430","article-title":"Real-world analysis of medications inducing meibomian gland dysfunction: based on the FDA adverse event reporting system database","author":"Li","year":"","journal-title":"Expert Opin. Drug Saf."},{"key":"B20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","article-title":"Pleiotropic effects of statins","volume":"45","author":"Liao","year":"2005","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn\u2019s disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"638444","DOI":"10.3389\/fimmu.2021.638444","article-title":"Efficacy and safety of Adalimumab biosimilars: current critical clinical data in rheumatoid arthritis","volume":"12","author":"Lu","year":"2021","journal-title":"Front. Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1093\/eurheartj\/ehy182","article-title":"Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract","volume":"39","author":"Mach","year":"2018","journal-title":"Eur. Heart J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.4103\/ijo.IJO_1784_22","article-title":"Enzymatic and biochemical properties of lens in age-related cataract versus diabetic cataract: a narrative review","volume":"71","author":"Mishra","year":"2023","journal-title":"Indian J. Ophthalmol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"803","DOI":"10.5414\/CP202396","article-title":"Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophageal reflux disease: a systematic review and meta-analysis","volume":"53","author":"Qi","year":"2015","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/qjmed\/hcg064","article-title":"Cataract and the use of statins: a case-control study","volume":"96","author":"Smeeth","year":"2003","journal-title":"QJM"},{"key":"B28","first-page":"269","article-title":"The effect of drugs used in treatment of skin disorders on visual system","volume":"40","author":"Szostakiewicz-Grabek","year":"2016","journal-title":"Pol. Merkur Lek."},{"key":"B29","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3389\/fphar.2019.00466","article-title":"Medicinal plants and natural products used in cataract management","volume":"10","author":"Tewari","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/s0039-6257(00)00128-4","article-title":"Susruta\u2019s role in the development of cataract surgery","volume":"44","author":"Thakur","year":"2000","journal-title":"Surv. Ophthalmol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1472-8206.2006.00397.x","article-title":"Effect of inhaled corticosteroids on risk of development of cataract: a meta-analysis","volume":"20","author":"Uboweja","year":"2006","journal-title":"Fundam. Clin. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.ophtha.2012.12.030","article-title":"Attributes associated with eye care use in the United States: a meta-analysis","volume":"120","author":"Wagner","year":"2013","journal-title":"Ophthalmology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ophtha.2008.12.001","article-title":"Use of inhaled and oral corticosteroids and the long-term risk of cataract","volume":"116","author":"Wang","year":"2009","journal-title":"Ophthalmology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1436183","DOI":"10.3389\/fphar.2025.1436183","article-title":"Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1080\/14740338.2023.2223952","article-title":"Post-marketing safety concerns with Upadacitinib: a disproportionality analysis of the FDA adverse event reporting system","volume":"22","author":"Wu","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e0274939","DOI":"10.1371\/journal.pone.0274939","article-title":"Risk factors affecting cataract surgery outcome: the Malaysian cataract surgery registry","volume":"17","author":"Yong","year":"2022","journal-title":"PLoS One"},{"key":"B37","doi-asserted-by":"publisher","first-page":"701507","DOI":"10.3389\/fonc.2021.701507","article-title":"Lenalidomide and Rituximab regimen combined with intravitreal methotrexate followed by Lenalidomide maintenance for primary vitreoretinal lymphoma: a prospective phase II study","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"111371","DOI":"10.1016\/j.biopha.2021.111371","article-title":"The therapeutic use of quercetin in ophthalmology: recent applications","volume":"137","author":"Zhao","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"B39","doi-asserted-by":"publisher","first-page":"04100","DOI":"10.7189\/jogh.14.04100","article-title":"The burden, causes, and determinants of blindness and vision impairment in asia: an analysis of the global burden of disease study","volume":"14","author":"Zou","year":"2024","journal-title":"J. Glob. Health"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1498191\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:11:35Z","timestamp":1745453495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1498191\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":39,"alternative-id":["10.3389\/fphar.2025.1498191"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1498191","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"article-number":"1498191"}}